FDA Orange Book
Is there a generic for Focinvez?
Focinvez contains fosaprepitant dimeglumine. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Focinvez (fosaprepitant dimeglumine). The Orange Book shows its last listed patent expires January 11, 2039.
Run it in Rivvi
Map Focinvez and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Focinvez products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| solution, intravenous | EQ 150MG BASE/50ML (EQ 3MG BASE/ML) | Marketed (Rx) | None | 0 | None |
NDA 216686, held by STERISCIENCE PTE LTD. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Focinvez patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 12042504 | January 11, 2039 | Drug product | None | 216686 |
| 11065265 | January 11, 2039 | Drug product | None | 216686 |
Focinvez NDC codes
Questions
Is there a generic for Focinvez?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Focinvez (fosaprepitant dimeglumine). The Orange Book shows its last listed patent expires January 11, 2039.
What is the generic name for Focinvez?
The active ingredient in Focinvez is fosaprepitant dimeglumine, per the FDA Orange Book.
When does the Focinvez patent expire?
The last patent listed for Focinvez in the Orange Book expires January 11, 2039. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.